What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?